AI Peer Review for Cardiology Manuscripts
Cardiology reviewers are tough on endpoints and trial design. Catch the issues that sink cardiovascular papers before an editor ever sees them.
Cardiovascular research lives or dies by its endpoints. A trial powered for a surrogate marker like ejection fraction or a biomarker, when the field wants hard outcomes like cardiovascular death or hospitalization, draws an immediate reviewer challenge. So does a composite endpoint that turns out to be driven entirely by its least important component.
ManuscriptMind reads your cardiology manuscript the way a critical reviewer would: checking whether your design supports your claims, whether your statistics handle competing risks and censoring correctly, and whether your conclusions stay inside what the data can bear.
What reviewers flag in Cardiology papers
Surrogate endpoints standing in for hard outcomes
Powering a study on ejection fraction, blood pressure, or a circulating biomarker and then claiming benefit for clinical outcomes. Reviewers ask whether the surrogate is validated and whether the inference to mortality or events is justified.
Composite endpoints that hide the real signal
A primary composite of death, myocardial infarction, and revascularization can look positive while being driven entirely by the softest, most operator-dependent component. Reviewers want the components reported separately.
Underpowered trials and registries
Sample size justified for a large effect that no one expects, or an observational registry analysis with too few events per variable to support the adjustment model.
Inadequate confounding control in observational work
Registry and cohort studies that adjust for an arbitrary list of covariates without a stated causal model, leaving obvious confounders unaddressed.
Intention-to-treat versus per-protocol confusion
Reporting a per-protocol result as if it were the primary analysis, or switching between populations without explanation when results diverge.
Statistical pitfalls specific to Cardiology
- Treating competing risks (cardiac death versus non-cardiac death) with standard Kaplan-Meier instead of a competing-risks framework
- Multiplicity across many prespecified and post hoc subgroups without correction
- Per-protocol analysis presented as primary when intention-to-treat is the appropriate standard
- Time-to-event analysis with informative censoring left unexamined
Reporting guidelines we check against
What ManuscriptMind checks in your Cardiology manuscript
- Whether your primary endpoint supports the clinical claim you make from it
- Whether composite endpoint components are reported and interpreted individually
- Sample size and event count against the complexity of your model
- Confounding control and the stated rationale for covariate selection
- Consistency between your intention-to-treat and per-protocol reporting
Review your Cardiology manuscript before you submit
Upload your paper and get structured, severity-classified feedback in minutes. Methodology, statistics, and literature issues flagged with specific fixes. Free during beta.
Frequently asked questions
Does ManuscriptMind understand cardiology endpoints?
Yes. The review specifically evaluates whether surrogate endpoints are appropriate, whether composite endpoints are reported by component, and whether your statistical handling of time-to-event and competing-risks data is sound for cardiovascular outcomes.
Will it check my survival analysis?
It flags common survival-analysis problems such as ignored competing risks, informative censoring, and proportional-hazards assumptions that go unstated. It points you to what a reviewer would question; it does not re-run your analysis.
Can it review observational registry studies, not just trials?
Yes. For registry and cohort work it focuses on confounding control, events-per-variable, and whether causal language is justified by an observational design.
Is my unpublished trial data kept confidential?
ManuscriptMind never trains on your manuscripts and deletes data on request. Your unpublished cardiovascular work stays yours.